Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
04 May 2022 - 10:00PM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announces the appointment of Dr.
Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective
immediately.
“Jo Brewer is an exceptional scientific leader, and I am
delighted that she has accepted the newly created CSO role, leading
our ongoing scientific research, and developing future autologous
and allogeneic therapies,” said Adrian Rawcliffe, Adaptimmune’s
Chief Executive Officer. “Jo has a strong track record of building
successful teams, driving innovation in cell therapy, as she worked
on all of our autologous clinical programs and developed our
allogeneic iPSC T-cell therapy platform. She has played a crucial
role in our collaborations with Astellas and Genentech.”
Most recently, Dr. Brewer served as Senior Vice President,
Allogeneic Research at Adaptimmune since December 2019. In this
role, she built the Allogeneic Research organization from the
ground up and took the concept of iPSC-derived allogeneic T-cell
therapies from an idea into the potential for an allogeneic
candidate in the clinic. Prior to her SVP role, Dr. Brewer held a
series of senior managerial roles within Adaptimmune’s research
organization. Her experience in immunotherapy and cell therapy at
Adaptimmune and its predecessor companies spans more than 20 years
and includes roles across the breadth of discovery. Before
focussing solely on the allogeneic platform for the last three
years, Dr. Brewer was one of the founding scientists at Adaptimmune
who built multiple research teams working on the development of
SPEAR T-cell therapies including NY-ESO (transitioned to GSK in
2018), ADP-A2M4 and ADP-A2AFP, as well as early next-generation
approaches including the ADP-A2M4CD8 construct. Prior to joining
Adaptimmune in 2009, Dr. Brewer held positions at Avidex, Medigene,
and Immunocore. She holds a master’s degree in Natural Sciences,
and a Ph.D. in cellular signalling, both from the University of
Cambridge, U.K.
About Adaptimmune Adaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking Statements This release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission for the year
ended December 31, 2021, our Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and other filings with the Securities
and Exchange Commission. The forward-looking statements contained
in this press release speak only as of the date the statements were
made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts: Media
Relations: Sébastien Desprez — VP, Corporate
Affairs and Communications T: +44 1235 430 583 M: +44
7718 453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D.
— VP, Investor Relations T: +1 215 825 9310 M: +1
215 460 8920 Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024